1. Medtech Insight
  2. >>Leadership

Filling The Device Sector's Diversity Gap: MedTech Color Builds Support

 
• By David Filmore

MedTech Color is focused on enhancing diversity in the device and diagnostics space and increasing thought leadership opportunities for people of color in the industry. The organization held a launch event at this year's MedTech Conference in Philadelphia, where Medtech Insight caught up with founder Kwame Ulmer.

Kawme Ulmer Interview Screenshot
Kwame Ulmer talks about strategies for improving diversity in medtech • Source: Ferdous Al-Faruque

The device sector has fallen behind other industries in addressing the lack of ethnic diversity among its executives and entrepreneurs, and directed efforts are needed to address the gaps. That's the message from Kwame Ulmer and others who officially launched a new group last week called MedTech Color to help tackle the issue.

Medtech Insight caught up with Ulmer, a device industry consultant and former US FDA official, at the breakfast launch event...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Medtech Insight

Execs On The Move: 26-30 May 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Where Do Questions Surrounding The EU’s AI Act Leave The Medtech Industry?

 
• By Amanda Maxwell

The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.

HistoSonics’ Edison System Gains Limited UK Access, While Awaiting CE Marking

 
• By Shubham Singh

While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.